Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 48.6
(8.0%)
SEK 48.6
(8.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.54 Million SEK | 117.95% |
| 2022 | -65.45 Million SEK | -47.03% |
| 2021 | -44.99 Million SEK | 38.27% |
| 2020 | -72 Million SEK | -58.31% |
| 2019 | -45.5 Million SEK | -17.0% |
| 2018 | -39.79 Million SEK | -8.35% |
| 2017 | -35.32 Million SEK | 5.24% |
| 2016 | -37.29 Million SEK | -80.83% |
| 2015 | - SEK | -212.77% |
| 2014 | -17.04 Thousand SEK | -2980.33% |
| 2013 | - SEK | 13521.0% |
| 2012 | -1705.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -42.47 Million SEK | -53.82% |
| 2024 Q1 | -27.61 Million SEK | 32.48% |
| 2023 Q2 | -28.61 Million SEK | -28.52% |
| 2023 FY | - SEK | -112.56% |
| 2023 Q4 | -55.03 Million SEK | -79.37% |
| 2023 Q3 | -30.68 Million SEK | -7.23% |
| 2023 Q1 | -22.26 Million SEK | 44.2% |
| 2022 Q2 | 1.96 Million SEK | 110.4% |
| 2022 Q4 | -39.9 Million SEK | -429.08% |
| 2022 FY | - SEK | -47.03% |
| 2022 Q1 | -18.85 Million SEK | -18.69% |
| 2022 Q3 | -7.54 Million SEK | -484.4% |
| 2021 Q4 | -15.88 Million SEK | -3778.01% |
| 2021 FY | - SEK | 38.27% |
| 2021 Q1 | 656 Thousand SEK | 102.49% |
| 2021 Q3 | 432 Thousand SEK | 101.49% |
| 2021 Q2 | -28.96 Million SEK | -4514.63% |
| 2020 Q1 | 1.46 Million SEK | 105.4% |
| 2020 Q3 | -18.32 Million SEK | 33.74% |
| 2020 Q4 | -26.37 Million SEK | -43.96% |
| 2020 FY | - SEK | -58.31% |
| 2020 Q2 | -27.65 Million SEK | -1983.72% |
| 2019 Q4 | -27.19 Million SEK | -167.55% |
| 2019 Q3 | -10.16 Million SEK | -41.71% |
| 2019 Q2 | -7.17 Million SEK | -2839.75% |
| 2019 FY | - SEK | -17.0% |
| 2019 Q1 | -244 Thousand SEK | 98.96% |
| 2018 Q3 | -7.3 Million SEK | -590.54% |
| 2018 Q1 | -8.94 Million SEK | -0.96% |
| 2018 FY | - SEK | -8.35% |
| 2018 Q4 | -23.51 Million SEK | -221.73% |
| 2018 Q2 | 1.49 Million SEK | 116.67% |
| 2017 Q2 | -13.62 Million SEK | -62.96% |
| 2017 Q1 | -8.35 Million SEK | 37.16% |
| 2017 FY | - SEK | 5.24% |
| 2017 Q3 | -4.36 Million SEK | 67.94% |
| 2017 Q4 | -8.85 Million SEK | -102.77% |
| 2016 Q4 | -13.3 Million SEK | -68.37% |
| 2016 Q2 | -10.97 Million SEK | -17601.61% |
| 2016 Q1 | -62 Thousand SEK | -100.6% |
| 2016 FY | - SEK | -80.83% |
| 2016 Q3 | -7.9 Million SEK | 28.02% |
| 2015 Q3 | 10.29 Million SEK | 294371.43% |
| 2015 Q1 | -3500.00 SEK | 0.0% |
| 2015 FY | - SEK | -212.77% |
| 2015 Q4 | 10.29 Million SEK | 0.0% |
| 2015 Q2 | -3500.00 SEK | 0.0% |
| 2014 FY | - SEK | -2980.33% |
| 2013 FY | - SEK | 13521.0% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | 151.643% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 103.638% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 104.095% |
| Xintela AB (publ) | -53.47 Million SEK | 121.599% |
| Active Biotech AB (publ) | -43.88 Million SEK | 126.315% |
| Amniotics AB (publ) | -27.14 Million SEK | 142.549% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 181.234% |
| BioArctic AB (publ) | 275.38 Million SEK | 95.806% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 103.14% |
| Camurus AB (publ) | 562.54 Million SEK | 97.947% |
| Cantargia AB (publ) | -284.31 Million SEK | 104.062% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 158.987% |
| CombiGene AB (publ) | -35.33 Million SEK | 132.683% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 108.199% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 167.599% |
| Genovis AB (publ.) | 64.57 Million SEK | 82.115% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 110.051% |
| Mendus AB (publ) | -97.84 Million SEK | 111.803% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 131.193% |
| Intervacc AB (publ) | -68.98 Million SEK | 116.743% |
| Kancera AB (publ) | -61.88 Million SEK | 118.661% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 143.121% |
| LIDDS AB (publ) | -39.67 Million SEK | 129.113% |
| Lipum AB (publ) | -37.11 Million SEK | 131.113% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 195.415% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 63.224% |
| NextCell Pharma AB | -40.98 Million SEK | 128.178% |
| OncoZenge AB (publ) | 7.26 Million SEK | -58.946% |
| Saniona AB (publ) | -69.69 Million SEK | 116.571% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 106.801% |
| Ziccum AB (publ) | -20.34 Million SEK | 156.774% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -577350.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 104.86% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 655.24% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 185.988% |
| Corline Biomedical AB | -1.69 Million SEK | 782.969% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 106.663% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 121.073% |
| Aptahem AB (publ) | -10 Million SEK | 215.384% |
| Fluicell AB (publ) | -25.91 Million SEK | 144.567% |
| Biovica International AB (publ) | -119.5 Million SEK | 109.664% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 127.352% |
| AcouSort AB (publ) | -16.7 Million SEK | 169.143% |
| Abliva AB (publ) | -93.6 Million SEK | 112.338% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 103.619% |
| 2cureX AB (publ) | -35.13 Million SEK | 132.869% |
| I-Tech AB | 30.34 Million SEK | 61.941% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 101.616% |
| Cyxone AB (publ) | -20.41 Million SEK | 156.574% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 111.272% |
| Biosergen AB | 228 Thousand SEK | -4965.351% |
| Nanologica AB (publ) | -62.11 Million SEK | 118.592% |
| SynAct Pharma AB | -222.7 Million SEK | 105.186% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 126.331% |
| BioInvent International AB (publ) | -312.7 Million SEK | 103.693% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -3632.552% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -27398.274% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 104.986% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 231.053% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 110.639% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 200.698% |